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Behavioral/Cognitive

Inflammatory Pain Promotes Increased Opioid
Self-Administration: Role of Dysregulated Ventral Tegmental
Area  Opioid Receptors
Lucia Hipólito,1 Adrianne Wilson-Poe,1 Yolanda Campos-Jurado,2 XElaine Zhong,1 Jose Gonzalez-Romero,1
Laszlo Virag,1 Robert Whittington,1 Sandra D. Comer,3 Susan M. Carlton,4 Brendan M. Walker,5 Michael R. Bruchas,6
and Jose A. Morón1
1

Department of Anesthesiology, Columbia University, New York, New York 10032, 2Departament de Farmàcia i Tecnología Farmacèutica, Facultat de
Farmàcia, Universitat de Farmàcia, 46100 Burjassot, València, Spain, 3Department of Psychiatry, Division on Substance Abuse, New York State Psychiatric
Institute, College of Physicians and Surgeons of Columbia University, New York, New York 10032, 4Department of Neuroscience & Cell Biology, University
of Texas Medical Branch Galveston, Galveston, Texas 77555, 5Department of Psychology and Graduate Program in Neuroscience, Washington State
University, Pullman, Washington 99164, and 6Department of Anesthesiology and Department of Anatomy and Neurobiology, Washington University Pain
Center, Washington University School of Medicine, St. Louis, Missouri 63110

Pain management in opioid abusers engenders ethical and practical difficulties for clinicians, often resulting in pain mismanagement.
Although chronic opioid administration may alter pain states, the presence of pain itself may alter the propensity to self-administer
opioids, and previous history of drug abuse comorbid with chronic pain promotes higher rates of opioid misuse. Here, we tested the
hypothesis that inflammatory pain leads to increased heroin self-administration resulting from altered mu opioid receptor (MOR)
regulation of mesolimbic dopamine (DA) transmission. To this end, the complete Freund’s adjuvant (CFA) model of inflammation was
used to assess the neurochemical and functional changes induced by inflammatory pain on MOR-mediated mesolimbic DA transmission
and on rat intravenous heroin self-administration under fixed ratio (FR) and progressive ratio (PR) schedules of reinforcement. In the
presence of inflammatory pain, heroin intake under an FR schedule was increased for high, but attenuated for low, heroin doses with
concomitant alterations in mesolimbic MOR function suggested by DA microdialysis. Consistent with the reduction in low dose FR heroin
self-administration, inflammatory pain reduced motivation for a low dose of heroin, as measured by responding under a PR schedule of
reinforcement, an effect dissociable from high heroin dose PR responding. Together, these results identify a connection between inflammatory pain and loss of MOR function in the mesolimbic dopaminergic pathway that increases intake of high doses of heroin. These
findings suggest that pain-induced loss of MOR function in the mesolimbic pathway may promote opioid dose escalation and contribute
to opioid abuse-associated phenotypes.
Key words: dopamine;  opioid receptor; opioids; pain; self-administration; VTA

Significance Statement
This study provides critical new insights that show that inflammatory pain alters heroin intake through a desensitization of MORs
located within the VTA. These findings expand our knowledge of the interactions between inflammatory pain and opioid abuse
liability, and should help to facilitate the development of novel and safer opioid-based strategies for treating chronic pain.

Introduction
Abuse of prescription opioids as well as heroin is at an all-time
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tion, 2014). Moreover, recent data from the National Survey on
Drug Use and Health revealed that 80% of new heroin drug users
had previously abused prescription opioids, suggesting a possible
link between prescription analgesic misuse and heroin use. Reports and case studies have revealed that the analgesic effects of
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opioids are reduced in drug-abusing individuals; and although
chronic opioid administration may alter pain states, the presence
of pain itself clearly alters the propensity to self-administer opioids (Rosenblum et al., 2003; Potter et al., 2008; Comer et al.,
2010; Chang and Compton, 2013). Rosenblum et al. (2003) have
reported that the prevalence of chronic pain in patients under methadone maintenance programs is ⬃80%. Interestingly, 30% of these
patients reported illegal use of opioids while they were in pain. This is
consistent with the notion that prior exposure to opioids is the best
predictor for both current and lifetime opioid misuse in chronic pain
patients (Turk et al., 2008; Boscarino et al., 2010).
Chronic mu opioid receptor (MOR) agonist administration is
associated with a partial loss in MOR function, which contributes
to the development of morphine tolerance. Indeed, the development of tolerance and desensitization of MORs are part of the
core features of addiction (for details, see Christie, 2008). Interestingly, several reports using animal models of inflammatory
pain have also revealed desensitization of MORs in DRG neurons, locus ceruleus, and the spinal cord, resulting in reduced
antinociceptive effects of MOR agonists (Hurley and Hammond,
2001; Shaqura et al., 2004; Zhang et al., 2004b; Jongeling et al.,
2009; Aoki et al., 2014). Based on these findings, we hypothesize
that inflammatory pain could also dysregulate MOR function in
the mesolimbic dopaminergic pathway, which in turn would
modify the reinforcing properties of opioids by altering their
intake pattern, especially in animals with a previous history of
opioid use.
The mesolimbic pathway is a key region in the modulation of
opioid addiction, which makes it an ideal circuit to investigate the
mechanisms underlying opioid abuse in the presence of pain
(Wise et al., 1995; Cui et al., 2014; Fields and Margolis, 2015).
Surprisingly, few studies have directly investigated how chronic
pain alters MOR function in the mesolimbic dopaminergic pathway. Studies by Narita and collaborators (Ozaki et al., 2002; Narita et al., 2005) investigated the effect of neuropathic pain on the
rewarding properties of morphine. By using conditioned place
preference (CPP) combined with microdialysis and GTP␥S techniques, the authors concluded that, in the presence of neuropathic pain, morphine showed reduced rewarding properties at
regular doses (8 mg/kg, s.c.) with a concomitant loss of
morphine-induced DA release in the nucleus accumbens (NAc)
due to reduced MOR function in the ventral tegmental area
(VTA). In contrast, a recent study (Wu et al., 2014) used a spared
nerve injury (SNI) model of neuropathic pain and showed that
similar doses (5 mg/kg s.c. and 7.5 mg/kg s.c.) exhibited the same
ability to induce morphine CPP in SNI rats compared with sham
rats. However, in the same study, the authors showed decreased
sensitivity to morphine in the injured rats group when the selected dose was 3.5 mg/kg, and this effect was probably mediated
by an abnormal increase of TNF-␣ levels in NAc. Nonetheless, no
prior studies have focused directly on examining the impact of
pain on subjects with prior exposure to opioids, a population that
may be more vulnerable to alterations in MOR sensitivity. Here,
we investigated the functional changes induced by inflammatory
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pain in MORs located in the mesolimbic pathway. We found that
pain impacts function of MORs in the VTA with a concomitant
loss of opioid-induced dopamine (DA) release in NAc. Next, we
found that the presence of inflammatory pain dramatically impacts both opioid intake and associated motivated behavior in a
dose-dependent manner.

Materials and Methods
Rat housing and surgery
A total of 182 male Sprague Dawley rats (300 –340 g at the time of the
surgery, Harlan) were individually housed with a 12/12 h dark/light cycle
and acclimated to the vivarium for at least 7 d before any manipulation.
Rats received food ad libitum until 2 d before starting the behavioral
studies, when food restriction (20 g of rat chow per day) commenced and
continued until the end of the experiment.
All surgeries were performed under isoflurane (1.5 MAC) anesthesia
under aseptic conditions. Rats were stereotaxically (Stoelting) implanted
with a CMA 12 (Harvard Apparatus) guide cannula targeting the NAc
core (coordinates: anteroposterior ⫽ 1.5 mm, mediolateral ⫽ ⫾1.4 mm,
dorsoventral ⫽ ⫺6.0 mm from the skull surface) (Paxinos and Watson,
2007; Hipólito et al., 2008) and with an indwelling jugular catheter for
microdialysis experiments or solely with an intrajugular catheter for selfadministration procedures. Cannula guides were implanted in a counterbalanced fashion for hemisphere. Catheter patency was maintained by
0.5 ml daily infusions of heparinized (62.5 IU/ml) saline and gentamycin
(1.5 mg/ml). Only animals confirmed to have correct microdialysis cannula placement, patent intravenous catheters (assessed using i.v. 28
mg/kg xylazine, Xilagesic 2%, Calier) and animals that completed all
training and tests in self-administration procedures were included in the
final data and statistical analyses.
In the DAMGO-induced DA release in the NAc and VTA experiments,
48 h before the experiment, rats were implanted stereotaxically with
unilateral vertical concentric-style microdialysis probes containing 2
mm of active membrane (Hospal AN69; molecular cutoff 60,000 Da)
into the NAc core (anteroposterior ⫽ 1.5 mm, mediolateral ⫽ ⫾1.6 mm
from bregma; and dorsoventral ⫽ 8.0 mm from dura (Paxinos and Watson, 2007). Microdialysis probes were implanted in a counterbalanced
fashion for hemisphere. In a separate experiment, animals were implanted with a unilateral microdialysis probe in NAc core and with an
injection cannula (26G, Plastics One) aiming at the posterior VTA (anteroposterior ⫽ ⫺6.1 mm, mediolateral ⫽ ⫺2.1 mm, dorsoventral ⫽
⫺8.1 mm angled 10° from perpendicular axes (Paxinos and Watson,
2007; Hipólito et al., 2008, 2011).
We selected the complete Freund adjuvant (CFA) model of inflammatory pain. CFA (Calbiochem) was diluted in the same volume of sterile
saline before its subcutaneous injection of 0.1 ml in the plantar surface of
the hindpaw (Parent et al., 2012; Hipólito et al., 2015).
All procedures were approved by the Columbia University Institutional Animal Care and Use Committee in accordance with the National
Institutes of Health Guidelines for the Care and Use of Laboratory
Animals.

Microdialysis and histology
Heroin-induced DA release in the NAc. Five days upon recovery from
surgery, rats were injected with saline or the CFA into the plantar surface
of the hindpaw. Forty-eight hours later, the rats were placed in Plexiglas
bowls (BASi) and the intravenous line was connected to a syringe by
using P50 tubing. Microdialysis probes (CMA12, 2 mm) were inserted
through the guide (Virag and Whittington, 2002) cannula, and artificial
CSF (Harvard Apparatus) was continuously perfused at 2.0 l/min during the entire experiment. Following a minimum stabilization period of
2 h upon probe insertion, samples were collected every 15 min and extracellular DA levels were determined by using offline HPLC with electrochemical detection as described previously (Virag and Whittington,
2002; Hipólito et al., 2008). Once DA baseline level was established (defined as 3 consecutive samples with ⬍10% variation in DA content), a
single intravenous heroin dose (75 or 150 g/kg) was administered and
DA levels in the dialysates were analyzed every 15 min for a total experimental time of 90 min.
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At the end of the microdialysis experiments, rats were first tested for
the patency of their intravenous catheters and then were killed, and the
brains removed and rapidly frozen in dry ice; 40-m-thick coronal slices
of the NAc core were obtained using a cryostat and stained with cresyl
violet to verify proper cannula placement.
DAMGO-induced DA release in the NAc and VTA. Forty-eight hours
before the experiment, rats were injected with either saline or CFA as
described above at the same time that the stereotaxic surgery was performed. On the day of the experiment, rats were placed in Plexiglas bowls
and microdialysis probes were continuously perfused at 3.0 l/min during the entire experiment. Following a minimum stabilization period of
2 h, samples were collected every 20 min and extracellular DA levels were
determined by using online HPLC with electrochemical detection as
described previously (Hipólito et al., 2008). Once the DA baseline level
was established (defined as 4 consecutive samples with ⬍10% variation
in DA content), a single intracranial DAMGO dose (6.7 ng/200 nl or 66.8
ng/200 nl) was administered either in the posterior VTA or perfused for
20 min through the microdialysis probe into the NAc core (10 M)
(Hipólito et al., 2008, 2009). Doses administered in the NAc core and in
the VTA were calculated from previously published data (Latimer et al.,
1987; Hirose et al., 2005; Hipólito et al., 2008). DA levels in the dialysates
were analyzed every 20 min for a total experimental time of 80 –100 min.
At the end of the experiments, rats were killed, and brains were removed
for histological confirmation of the microdialysis probe and cannula
placement as described above.

Brain slice preparation and electrophysiology
In vitro electrophysiological experiments on brain slices were conducted
48 h after CFA or saline injection in the hindpaw. Male Sprague Dawley
rats (23- to 30-d-old) were deeply anesthetized with isoflurane and decapitated. Brains were quickly removed and submerged in ice-cold
sucrose-buffered artificial CSF (in mM as follows: 254 sucrose, 3 KCl, 1.25
NaH2PO4, 10 D-glucose, 24 NaHCO3, 2 CaCl2, and 2 MgSO4). Coronal
midbrain sections (230 –250 m) that contained the VTA were cut using
a vibratome (VT1200S, Leica Microsystems) in ice-cold sucrose-buffered
artificial CSF. VTA slices were submerged in ACSF (in mM as follows: 126
NaCl, 2.5 KCl, 1.4 NaH2PO4, 1.2 MgCl2, 2.4CaCl2, 11 glucose, and 25
NaHCO3) at 34°C for 1 h, and equilibrated with 95% O2 and 5% CO2
before maintenance at room temperature. Slices were then individually
transferred to the recording chamber (volume 0.8 ml) and superfused
continuously (2.2 ml/min) with 34°C ACSF.
Posterior VTA neurons were visualized using differential interference
contrast optics on an upright microscope (BX50WI, Olympus). Wholecell patch-clamp recordings of VTA neurons were obtained using an
Axopatch 200B amplifier (Molecular Devices). Electrodes (2– 4 M⍀)
were filled with pipette solution containing the following (in mM): 140
CsCl, 10 EGTA, 5 HEPES, 2 CaCl2, 1 MgCl2, 2 MgATP, and 3 QX-314
plus 0.05% biocytin. The internal solution had pH 7.3 and osmolality
280 –286 mOsm/l. Series resistance (⬍20 M⍀) was compensated by
70%. Recordings of spontaneous IPSCs (sIPSCs) were obtained in the
presence of DNQX (5 M) and strychnine (5 M) in the absence of
stimulation. DA neurons in the VTA are known to distinct firing properties compared with GABAergic neurons. Although the use of Cs-based
intracellular recording solution interfered with our ability to assess these
properties, we selectively recorded from large-diameter neurons in the
lateral posterior VTA, an area that sends dense projections to the NAc,
and in which DA neurons vastly outnumber GABA neurons. In these
experiments, a stable 5– 8 min recording was obtained before addition of
DAMGO for a 5– 8 min period. Each recording lasted ⬃20 min in total.
All recordings were filtered (2 kHz low-pass filter) and sampled (10 kHz)
for online and later offline analysis (Axograph X; Axograph Scientific
Software).

Heroin and sucrose self-administration procedures
Rat operant-conditioning chambers (Med Associates) were equipped
with two retractable levers positioned on the right-hand wall 12.5 cm
apart and 5 cm above the floor, a food magazine connected to a food
pellet dispenser, two cue lights positioned 2 cm above the levers, and one
house light positioned on the top left-hand wall. At the beginning of the
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session, both levers (active and inactive) were presented and a white light
was on above the active lever. Pressing the active lever resulted in drug
infusion and a 30 s retraction of both active and inactive levers, along
with the turning off of the light cue above the active lever 10 s after the
retraction of the levers. Pressing the inactive lever had no effect. After 5–7
d of recovery from surgery, animals began daily (6 –7 d a week) 2 h
sessions of sucrose self-administration under a fixed-ratio (FR) 1 schedule,
where levers were not retracted and the cue light was always on. Once rats
acquired the self-administration behavior (by obtaining 60 pellets/session on
3 consecutive sessions), rats were assigned to different experiments.
FR2 for sucrose. Rats continued 2 h FR1 sessions with sucrose as the
reinforcer until stable performance of the task was reached (defined as 5
consecutive completed sessions by obtaining 60 pellets/session). Then
the schedule of reinforcement was changed to FR2 for the other 3 sessions. Once they completed the training, the rats were injected with saline
or CFA; and 48 and 72 h later, they were tested for sucrose selfadministration according to a FR2 schedule.
Within-session FR2 heroin dose–response. Rats were given 2 h access to
heroin (50 g/kg/infusion) under an FR1 schedule. After stable drug
intake was obtained (defined as 5 consecutive sessions in which the number of infusions did not vary by ⬎15% of the mean value obtained across
those sessions), the schedule was switched to FR2 for 3 additional sessions. After this training, rats were injected with saline or CFA as described above; and 48 and 72 h later, they underwent 2 consecutive
within-session dose–response tests. Briefly, one of three doses of heroin
(50, 100, 200 g/kg/infusion) was made available for a 1 h time period
during the session, with a 15 min resting period between doses. Doses
were altered by varying the infusion duration. The presentation of the
doses was made in an ascending or descending manner at 48 or 72 h after
CFA-induced paw inflammation. The order of the presentation of doses
in ascending or descending manner was counterbalanced; thus, half of
the rats followed ascending order (50, 100, 200 mg/kg) 48 h after receiving CFA or saline in the hindpaw and followed descending order (200,
100, 50 mg/kg) 72 h after CFA or saline injection. The other half of the
rats followed descending order 48 h after CFA or saline administration
and ascending order 72 h after CFA or saline administration.
Progressive ratio (PR) for heroin or sucrose. Rats were given 2 h access to
heroin (50 g/kg/infusion) or sucrose under a FR1 schedule. After stable
drug intake was obtained (defined as 5 consecutive sessions in which the
number of infusions did not vary by ⬎15% of the mean value obtained
across those sessions), the schedule was switched to FR2 and FR5 for a
total of six additional sessions. The following day, the animals underwent
an initial PR session (baseline PR session). In the PR session, the number
of responses on the active lever to obtain the reward increased with the
dose. The increase in the number of correct responses followed the equation response ratio ⫽ (5 ⫻ e (0.2 ⫻ infusion number) ⫺ 5 rounded to the
nearest integer resulting in the following PR steps: 1, 2, 6, 9, 12, 15, 20, 25,
32, 40, 50, 62, 77, 95…(Roberts and Bennett, 1993). In the PR sessions,
the ordinal values of the final ratios (the PR step number) were determined because the actual ratio values are derived from an exponential
equation and they may violate assumptions of homogeneity of variance
in the statistical analysis (Roberts and Bennett, 1993). After the baseline
PR session, rats were injected with saline or CFA in the hindpaw; and 48 h
later, when inflammation was stable, the rats were placed again in the
self-administration chambers to undergo a second PR session. Two doses
of heroin, 50 g/kg/infusion and 200 g/kg/infusion, were tested in the
two PR sessions (baseline and after injection) in different groups of rats.

Plantar test for thermal sensitivity
Antinociceptive effects of heroin in the microdialysis experiments. The effects of CFA injection on the antinociceptive properties of heroin were
examined using the Plantar Test (Hargreaves method, IITC Life Science).
Rats were surgically implanted with a catheter into the internal left jugular vein. Following 5 d of recovery, rats were injected with saline or CFA
in the plantar surface of the hindpaw. Paw withdrawal thresholds (4
measurements with 5 min of resting period) were measured for 2 consecutive days before (baseline) and 48 h after (after intraplantar injection) saline or CFA injection. In the same session and after obtaining a
measurement of after intraplantar injection, 75 or 150 g/kg of heroin
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was infused through the intravenous line, and paw withdrawal thresholds
were measured every 5 min for a total time of 30 min. Briefly, animals
were placed in Plexiglas boxes on top of a glass surface. After 30 min of
habituation, a radiant heat source was focused on the plantar surface of
the hindpaw, and the latency of paw withdrawal from the radiant heat
stimulus was recorded. Four measurements with at least a 5 min interval
between trials were obtained for each session. The intensity of the light
beam was adjusted so that baseline latencies were ⬃10 s in naive rats. A
cutoff time of 30 s was imposed to prevent tissue damage.

Plantar test in self-administration experiments
Rats undergoing heroin self-administration under an FR2 schedule were
also tested for thermal sensitivity using the plantar test as described
above. Paw withdrawal thresholds were assessed 2 h before starting the
self-administration session. We measured paw withdrawal thresholds
before (three baseline measurements) and during self-administration
procedures (three measurements during heroin self-administration
training and two after CFA or saline injection in the hindpaw).

Data and statistical analysis

Microdialysis. Basal levels of DA (mean ⫾ SEM) were expressed as fmol in
10 l (analyzed sample volume) for heroin experiments and as fmol in 65
l in DAMGO experiments. Three or four (for heroin and DAMGO experiments, respectively) basal values were averaged to obtain a basal level for
each animal. Differences in basal levels between groups (saline and CFA
treated animals) were evaluated using the unpaired Student’s t test.
In all experiments, DA levels obtained before and after heroin intravenous administration or DAMGO intracranial administration were
transformed to percentages of baseline for each individual rat and were
statistically analyzed by a mixed two-way ANOVA for repeated measures,
with group (saline or CFA injection) taken as the between factor and time
the within-subjects factor. In the heroin intravenous administration experiments, significant effects of time were analyzed by two-way ANOVA
with repeated measures per each group followed by Dunnett’s post hoc
comparisons test, and the time ⫻ group interaction was further analyzed
using the Bonferroni multiple-comparisons test. In the DAMGO intracranial administration experiments, significant effects of time and
time ⫻ group interaction were further analyzed by Bonferroni multiplecomparisons test.
Areas under the curve (AUC) were calculated from 0 to 90 min for
each rat from percentage data and statistically analyzed by mixed twoway ANOVA with group and dose as between-subject factors. Significant
effects of group and the interaction group ⫻ dose were analyzed by
Bonferroni corrections for multiple comparisons.

Electrophysiology
For analysis, sIPSCs above a preset threshold (3.5 SDs above baseline
noise, and exceeding 13 pA) were automatically detected by a sliding
template algorithm and then manually checked offline. Mean amplitudes
and interevent intervals were calculated by analyzing events over the last
3 min of drug superfusion (before and during DAMGO). Normalized
cumulative distribution plots of IPSC interevent intervals were constructed and analyzed using the Kolmogorov–Smirnov test. Mean sIPSC
amplitudes were determined by Gaussian fits to amplitude histograms in
5 pA bins (as in Bobeck et al., 2014). All numerical data are expressed as
mean ⫾ SEM. All distributions were tested for normality using the Shapiro–Wilk normality test. Statistical comparisons between CFA and saline groups were made using Student’s t test, and comparisons to
normalized baseline were calculated using Wilcoxon signed rank test.

Self-administration under FR schedule
For the within-session heroin self-administration dose–response curves,
the total intake per dose was analyzed by using a three-way ANOVA with
repeated measures selecting group as a between-subject factor and dose
and order of presentation as within-subject factors. Because no statistical
differences were detected in the within-subject factor of order of presentation, data from both sessions were pooled and data were further analyzed by two-way ANOVA with group as a between factor and dose as a
within factor, followed by Bonferroni corrections for multiple comparisons when differences were detected.

For the sucrose self-administration experiments, active and inactive
lever responses were analyzed by using repeated-measures one-way
ANOVA, and time to complete the task was evaluated using unpaired
Student’s t test.

Self-administration under PR schedule
For the heroin and sucrose PR self-administration sessions, the PR step
number was analyzed by using a mixed two-way ANOVA with repeated
measures with group as a between-subjects factor and session (baseline
and after injection) as a within-subjects factor followed by Bonferroni
corrections for multiple comparisons when interactions were found to be
significant.

Thermal sensitivity
Paw withdrawal thresholds were evaluated using a mixed two-way
ANOVA with repeated measures with group as a between-subjects factor
and session number as a within-subjects factor followed by Bonferroni
corrections for multiple comparisons.
For all ANOVAs, homogeneity of variance was tested before an
ANOVA was performed, and the significance level was always set at p ⬍
0.05. Statistical analyses were performed with IBM SPSS statistics 20
software or GraphPad (Prism) software for Windows.

Results
Effects of inflammatory pain on heroin-evoked DA release
within the reward pathway
To test the hypothesis that inflammatory pain could dysregulate
the function of the mesolimbic dopaminergic pathway, we first
conducted in vivo microdialysis analyses to measure heroinevoked DA release in the NAc core in the presence of inflammatory pain (Fig. 1). Although several reports have investigated the
role of the DA increase in NAc shell versus NAc core in druginduced motivated behaviors (Everitt and Robbins, 2005), we
elected to focus on the NAc core given its role in instrumental
action according to the value of the predicted outcome and motivated behavior (Di Chiara, 2002; Saddoris et al., 2013). Fortyeight hours following the administration of CFA or saline
(control) in the rat hindpaw (n ⫽ 5 or 6 per group), a microdialysis probe targeting the NAc core was inserted, and extracellular
DA content in the dialysates was monitored every 15 min. Once a
stable baseline for DA was achieved (⬍10% variation in three
consecutive samples), one of two heroin doses (75 or 150 g/kg)
was administered through an intravenous line, and extracellular
DA levels were monitored for 90 min. Baseline DA levels
(mean ⫾ SEM) were calculated from a standard curve as 11.06 ⫾
1.25 fmol/10 l and 17.78 ⫾ 3.97 fmol/10 l for the control
versus inflamed group, respectively. These results indicate that
the presence of inflammation-induced pain does not have a significant effect on basal extracellular DA levels (n ⫽ 10 or 11, t test,
p ⫽ 0.125). Interestingly, we observed that, whereas the administration of intravenous heroin (75 g/kg) triggered an increase
in extracellular DA levels of 197.9% compared with baseline in
control rats, this same dose of heroin elicited a much smaller
increase in DA levels (117.3%) compared with baseline in CFAtreated rats (two-way ANOVA for repeated measures: withinsubject effect of time, F(8,72) ⫽ 4.841, p ⬍ 0.000; and interaction
of time ⫻ group, F(8,72) ⫽ 2.278, p ⫽ 0.031; Figure 1B). Indeed,
heroin-evoked DA release in the CFA-treated group was significantly lower than the control group (two-way ANOVA: betweensubject effect group, F(1,9) ⫽ 13.599, p ⫽ 0.005, n ⫽ 5 or 6) at 30
min ( p(30) ⫽ 0.048) and 45 min ( p(45) ⫽ 0.024) after infusion of
intravenous 75 g/kg heroin. These data suggest that inflammatory pain produces a robust attenuation of heroin-induced DA
release in the NAc at doses previously shown to be reinforcing
(Hemby et al., 1995; Martin et al., 1996; Caprioli et al., 2007).
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Figure 1. Inflammatory pain alters heroin-evoked release of DA in the NAc. A, Schematic of the experimental design for microdialysis experiments. Effect of 75 g/kg (B) and 150 g/kg (C)
intravenous heroin administration on DA levels in control (black) and in CFA-treated (red) animals. Data are mean ⫾ SEM represented as percentage from baseline; n ⫽ 5 or 6 per group. Heroin was
administered at time 0. *p ⬍ 0.05, significant differences from baseline (Dunnett’s test). #p ⬍ 0.05, significant differences between the two groups at a time point after heroin administration
(two-way ANOVA with repeated measures followed by Bonferroni multiple comparisons). D, Percentage change in DA levels induced by heroin calculated as AUC from 0 to 90 min for control (black)
and CFA-treated (red) animals at the two doses of heroin tested. At 75 g/kg of heroin, the AUC value was significantly lower in CFA-treated animals compared with control animals. #p ⬍ 0.05
(two-way ANOVA followed by Bonferroni multiple comparisons). Doubling the heroin dose in CFA-treated rats increased the value of the AUC significantly (*p ⬍ 0.05) but did not change the value
obtained in control rats receiving 75 g/kg. The AUC for CFA-treated rats receiving 150 g/kg heroin is significantly higher versus AUC for control rats receiving 150 g/kg heroin ( #p ⬍ 0.05). E,
Diagram of coronal sections indicating the placement of microdialysis probes in the NAc core. Probe locations for control (black) and CFA-treated (red) rats receiving 75 g/kg of heroin are
represented in the left hemisphere, whereas probe locations for control and CFA-treated rats receiving 150 g/kg of heroin are represented in the right hemisphere. In some cases, one plotted line
corresponds to more than one dialysis membrane. Numbers to the side of the coronal sections indicate distance anterior to bregma. Adapted from the rat brain atlas of Paxinos and Watson (2007).

While previous reports have found a reduction in release of DA in
the NAc following the administration of an 8 mg/kg morphine
subcutaneous challenge in rodents with neuropathic pain (Ozaki
et al., 2002; Ozaki et al., 2003), the effects of higher doses of
opioids have not been previously examined. Therefore, we next
examined the effects of a higher dose of heroin (150 g/kg, i.v.)
on accumbal DA release in the NAc in control and in CFA-treated
rats (Fig. 1C). The highest dose of heroin induced a significant
increase in DA release in control rats and in CFA-treated rats
(two-way ANOVA for repeated measures: within-subjects effect
of time, F(8,64) ⫽ 11.828, p ⬍ 0.0001; and interaction of time ⫻
treatment, F(8,64) ⫽ 2.879 p ⫽ 0.008, n ⫽ 5; Figure 1C). Interestingly, animals experiencing inflammatory pain showed greater
increases in extracellular DA levels (154% from baseline) in comparison with control animals (131.9% from baseline), although
no overall significant differences between the two groups were

found (between-subjects effect of group, F(1,8) ⫽ 4.795, p ⫽
0.060). To further quantify this inflammatory pain-induced effect on the dose–response for heroin-evoked DA release, we calculated the AUC between 0 and 90 min for each treatment group
(Fig. 1D). This measure allowed us to compare the total effect on
DA extracellular levels in the NAc in inflammatory pain induced
by the administration of heroin in both groups. Our results further corroborated a different pattern of DA release in CFAtreated rats (two-way ANOVA: effect of group, F(1,17) ⫽ 0.002,
p ⫽ 0.965; effect of dose, F(1,17) ⫽ 4.505, p ⫽ 0.049; and interaction group ⫻ dose, F(1,17) ⫽ 18.964, p ⬍ 0.0001). Rats experiencing inflammatory pain had a robust reduction in accumbal DA
release at the lowest heroin dose tested ( p ⫽ 0.006), whereas they
showed a robust DA release when the dose of heroin was increased to 150 g/kg ( p ⫽ 0.007) compared with the control
group (Fig. 1D). Interestingly, there was no significant difference
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Figure 2. Antinociceptive properties of 75 (B) or 150 g/kg (C) of heroin in control and CFA-treated rats measured as paw withdrawal latencies to radiant heat stimulation. Schematic of the
experimental design is shown in A. Data are mean ⫾ SEM of paw withdrawal latency measured in seconds. #p ⬍ 0.05, differences between groups (Bonferroni multiple comparisons). n ⫽ 5 or 6
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in heroin-elicited accumbal DA release between control rats that
received 75 g/kg heroin and CFA-treated rats that received 150
g/kg heroin ( p ⫽ 0.125). Together, these results indicate that
rats suffering from inflammatory pain require larger doses of
opioid to produce a significant release of DA in the NAc.
Inflammatory pain does not affect antinociceptive properties
of heroin
Previous data have shown that pain relief, by blocking pain afferents with lidocaine, increases extracellular levels of DA in the NAc
(Navratilova et al., 2012). To elucidate whether CFA-induced
inflammation modifies the antinociceptive properties of heroin
at the same doses used in the microdialysis experiments, we determined the analgesic potency of heroin in a separate group of
rats using the plantar test (Fig. 2). We measured thermal sensitivity to radiant heat for two sessions (averaged as baseline) before injecting saline or CFA in the plantar surface of the hindpaw
(n ⫽ 5 or 6/group). Forty-eight hours following injection of CFA
or saline, thermal sensitivity was measured every 5 min for a total
period of time of 30 min before and after the intravenous administration of 75 or 150 g/kg of heroin. Hypersensitivity to heat
induced by CFA administration was significantly reversed by the
intravenous administration of 75 and 150 g/kg heroin; and interestingly, no difference was observed between the two heroin
doses tested (Fig. 2 B, C; two-way ANOVA for repeated measures:
within-subjects effect time point, F(8,144) ⫽ 18.507, p ⬍ 0.0001;
within-subjects effect time point ⫻ dose ⫻ treatment, F(8,144) ⫽
1.687, p ⫽ 0.106). Indeed, paw withdrawal thresholds after either
75 or 150 g/kg heroin intravenous administration were similar in
control and pain rats (two-way ANOVA: between-subjects effect of
treatment, F(1,18) ⫽ 1.778, p ⫽ 0.199; between-subjects effect of dose,
F(1,18) ⫽ 3.305, p ⫽ 0.086 and between-subjects effect dose ⫻ treatment, F(1,18) ⫽ 1.285, p ⫽ 0.272). These results indicate that the
inflammatory pain-induced alterations in DA transmission in the
NAc are not related to changes in the antinociceptive properties
of heroin. These data further support the idea that the presence of

inflammatory pain selectively impacts the sensitivity to the rewarding properties of heroin and that this effect is not due to
alterations in heroin-induced antinociception.
Inflammatory pain decreases DAMGO-induced release of DA
in the NAc when administered in the VTA but not when
locally administered in the NAc
Next, we conducted studies to identify the cellular mechanism
underlying the effects of CFA on heroin-evoked DA release in the
NAc core. DA release in the VTA-NAc pathway mediates the
reinforcing properties of drugs and natural reinforcers. This DA
release is tightly regulated, at least partially by MORs in this pathway (Johnson and North, 1992; Devine et al., 1993; Wise et al.,
1995; Le Merrer et al., 2009; Wassum et al., 2009; Olszewski et al.,
2011). We hypothesized that inflammatory pain may negatively
impact the function of MOR within the reward pathway and
thereby influence opioid-evoked DA release in the NAc. Thus, we
first analyzed the effect of inflammatory pain on accumbal DA
release induced by a single dose of the selective MOR agonist
DAMGO administered either in the NAc (via perfusion of
DAMGO 10 M) or in the VTA (via microinjection of 6.7 ng/200
nl) (Fig. 3B andFig. 3D, respectively).
Baseline DA levels (mean ⫾ SEM) were calculated from a standard curve as 66.4 ⫾ 11.7 fmol/65 l and 69.7 ⫾ 8.3 fmol/65 l for
the control versus inflamed group, respectively. In agreement with
the microdialysis data described above, our results indicate that the
presence of inflammatory pain does not have a significant effect on
basal extracellular DA levels (n ⫽ 10, t test, p ⫽ 0.823).
As expected (Hipólito et al., 2008), the administration of 10
M DAMGO in the NAc core triggered a significant increase in
DA release (up to 140% from baseline 60 and 80 min following
DAMGO administration, Dunnett’s test, p ⬍ 0.05 for time 60 and
time 80 compared with baseline; Fig. 3B) in saline-treated rats.
However, the effect of DAMGO was reduced in CFA-treated rats.
Although intra-NAc DAMGO triggered an increase up to 118%
from baseline, no significant differences were found with respect
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to baseline or compared with control rats (n ⫽ 5/group; mixed
two-way ANOVA between subjects (group) F(1,10) ⫽ 3.542, p ⬍
0.089; Figure 3B). In contrast, intra-VTA administration of 6.7 ng
DAMGO elicited a significant release of DA in the NAc in control
rats, and this effect was blunted in CFA-treated rats (Fig. 3D).
Indeed, mixed two-way ANOVA analysis detected differences between the two groups (group effect, F(1,8) ⫽ 12,133, p ⫽ 0.008 and
interaction time ⫻ group F(7,56) ⫽ 2.462, p ⫽ 0.006). Control rats
showed a significant increase in DA release in the NAc up to
125%–140% from baseline, which was initiated 20 min following
DAMGO administration and lasted until the end of the experiment. In CFA-treated rats, the administration of DAMGO intraVTA induced a much smaller increase in DA release that was not
significantly different from baseline (Bonferroni multiple comparisons, p(20) ⫽ 0.044, p(40) ⫽ 0.018, p(60) ⫽ 0.018, p ⫽ 0.004;
Fig. 3C). This loss of DAMGO effect was especially relevant 20
and 40 min following the administration of DAMGO locally in
the VTA (Bonferroni multiple comparisons between groups,
p(20) ⫽ 0.044 and p(40) ⫽ 0.004 vs control group; Fig. 3D).
Together, these data reveal a reduced ability of the MOR agonist DAMGO to increase DA release in the NAc, suggesting a
decrease in MOR function within the reward pathway in inflammatory pain. Interestingly, this loss of MOR function is more
evident in the VTA. To further study the plausible desensitization
of the MOR in the VTA in CFA-treated rats, we administered a
10⫻ higher dose of DAMGO in the VTA and monitored the DA
release in the NAc core. Intra-VTA administration of 66.8 ng
overcame the effects on DAMGO-induced DA release in the NAc
(Fig. 3E). Both saline and CFA-treated rats experienced a significant increase of DA extracellular levels from baseline after
DAMGO application (n ⫽ 5/group; mixed two-way ANOVA
within subjects (time), F(7,56) ⫽ 18.392, p ⬍ 0.001; Bonferroni
multiple comparisons from baseline: saline group, p(40) ⫽ 0.013
and p(60) ⫽ 0.032; CFA group, p(40) ⫽ 0.018). More interestingly,
the mixed two-way ANOVA analysis did not detect differences
between the two groups (group effect, F(1,8) ⫽ 0.241, p ⫽ 0.636;
and interaction time ⫻ group, F(7,56) ⫽ 0.488, p ⫽ 0.839), further
supporting the notion that the increase in the dose reverses the
CFA-induced effects.
Inflammatory pain diminishes MOR-mediated inhibition of
GABA release in the VTA
The results presented above suggest that the presence of inflammatory pain impacts the function of MOR within the reward
pathway, and more specifically in the VTA. DA neuron firing in
the VTA is tightly controlled by tonic GABA release, and GABAergic inhibition of DA neuron firing is reduced by the activation of
MORs (Gysling and Wang, 1983; Johnson and North, 1992; Jalabert et al., 2011; Matsui et al., 2014). To investigate whether
inflammatory pain affects MOR-mediated GABA transmission
in the VTA, we recorded sIPSCs in the VTA in control and CFAtreated rats. sIPSCs were readily observed in the presence of
4
(Figure legend continued.) between groups (Bonferroni multiple comparison). *p ⬍ 0.05, significant differences in the within-subjects effect of time for animals treated with saline or CFA
(Bonferroni multiple comparisons). C, Diagram of coronal sections indicating the placement of
microdialysis probes in the NAc for control (black) and CFA-treated (red) rats in the NAc DAMGO
infusion experiment. F, Diagram of coronal sections indicating the placement of microdialysis
probes in the NAc for control (black) and CFA-treated (red) rats in the intra-VTA injection of
DAMGO experiment. G, Diagram of coronal sections indicating microinjection cannula tips in
VTA for control (black) and CFA-treated (red) rats in the intra-VTA injection of DAMGO experiment. Bars and dots could represent more than one probe or cannula placement.
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DNQX and strychnine (Fig. 4A). As expected, superfusion of
DAMGO (1 M) decreased the frequency of sIPSCs in VTA neurons from saline-treated rats by 48% (Fig. 4A–D; p ⫽ 0.016, n ⫽
7) (Theile et al., 2011). The decrease in sIPSC frequency was
associated with a rightward shift in the cumulative probability
distribution of the sIPSC interevent intervals (Fig. 4C; p ⫽ 1.29,
Kolmogorov–Smirnov statistic for pre-DAMGO vs DAMGO).
DAMGO did not significantly diminish the frequency of sIPSCs
in neurons from CFA-treated rats (75% of pre-DAMGO levels;
Fig. 4 A, C,D; p ⫽ 0.094, n ⫽ 6; cumulative probability distribution of interevent intervals, p ⫽ 0.025, Kolmogorov–Smirnov
statistic for pre-DAMGO vs DAMGO). DAMGO also reduced
the amplitude of sIPSCs in saline-, but not CFA-treated, rats (Fig.
4C,D; p ⫽ 0.016 and 0.69, respectively; cumulative probability
distribution of amplitude for saline, p ⫽ 0.001; for CFA, p ⫽
0.003, Kolmogorov–Smirnov statistic for pre-DAMGO vs
DAMGO). In addition, DAMGO had no significant effect on the
IPSC kinetics in CFA or morphine-treated rats (Fig. 4A, inset).
These results show that DAMGO diminished the frequency and
amplitude of GABAergic sIPSCs in neurons from saline-treated
animals, as expected. This inhibition of GABA release was significantly diminished in CFA-treated neurons, which suggests desensitization of the MOR. To test the hypothesis that MOR
desensitization in CFA-treated slices could be overcome with a
higher concentration of MOR agonist, we repeated these experiments by superfusing 3 M DAMGO. As expected, superfusion of
DAMGO (3 M) decreased the amplitude and frequency of
sIPSCs in VTA neurons from saline treated animals by 80% and
49%, respectively (Fig. 4D; for amplitude, p ⫽ 0.031; for frequency, p ⫽ 0.031, n ⫽ 6). In contrast with our previous experiment using 1 M DAMGO, in neurons from CFA treated rats, 3
M DAMGO diminished the amplitude of sIPSCs (79% of preDAMGO levels; Fig. 4D; p ⫽ 0.031, n ⫽ 6). There was also a
robust decrease in the frequency of sIPSCs (43% of pre-DAMGO
levels; Fig. 4D; p ⫽ 0.031). Thus, increasing the concentration of
DAMGO to 3 M restored the loss of MOR-mediated inhibition
of GABA release in CFA-treated rats. Moreover, the DAMGOinduced decrease in GABA release was reversible by naloxone (3
M, Fig. 4E). These data further substantiate MOR desensitization in the VTA during inflammatory pain.
Inflammatory pain increases the self-administration of
higher doses of heroin
Next, we conducted intravenous heroin self-administration experiments to determine whether the above observed paininduced decrease in MOR-dependent accumbal DA release could
account for changes in the reinforcing effects of opioids in the
presence of pain. This is especially relevant in individuals with
prior opioid exposure because the presence of pain may affect the
reinforcing properties of the opioid, which can lead to changes in
the pattern of drug intake. To this end, we investigated the effects
of inflammatory pain in rats that had been trained under FR1 and
FR2 schedules of heroin reinforcement (50 g/kg) for at least 8
sessions (Fig. 5 A, C). Once the three sessions of heroin selfadministration under FR2 schedule were completed, rats were
injected with saline or CFA in the hindpaw, as described above,
and two within-session dose–response analyses were conducted
48 and 72 h after CFA or saline injection (Martin et al., 1996). All
rats completed two sessions of self-administration where they
were exposed to 50, 100, and 200 g/kg/infusion of heroin under
an FR2 schedule for 1 h in either an ascending or descending
order over 2 consecutive days (sessions were randomized in a
counterbalanced fashion). Importantly, throughout the experi-
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Figure 4. Inflammatory pain alters DAMGO inhibition of GABA release in the VTA. A, Recordings of sIPSCs before (Pre) and after addition of DAMGO (1 M) in two different VTA neurons from
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ment, we measured thermal sensitivity to heat using the plantar
test (Fig. 5B) before starting the self-administration session to
assess whether repeated self-administration of opioids alters
thermal sensitivity. We observed no opioid-induced hyperalgesia
resulting from prior heroin self-administration in either CFA- or
saline-injected rats as previously reported (Edwards et al., 2012).
As expected, the administration of CFA following at least 8 sessions of heroin self-administration produced a significant in-

crease in heat sensitivity. During these last 8 training sessions, rats
first showed to be able to distinguish between active and inactive
lever; and second, rats showed to present a stable heroin intake as
can be deducted for their stable response pattern on the active
lever during FR1 and doubling the number of responses only in
the active lever during the FR2 (Fig. 5C). Interestingly, we found
that inflammatory pain caused significant alterations in the pattern of heroin intake in a dose-dependent manner (n ⫽ 5 or
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6/group, F(2,27) ⫽ 4.104, p ⫽ 0.028) (Fig. 5D), regardless of the
order of dose presentation (F(2,27) ⫽ 0.020, p ⫽ 0.980). Salinetreated rats adjusted their number of infusions self-administered
to maintain their drug intake across doses showing a linear profile
when adjusted to a semilogarithmic scale (ascending: y ⫽ 5.647x
⫹ 14.7, R 2 ⫽ 0.9465; and descending: y ⫽ ⫺3.986 x ⫹ 11.2, R 2 ⫽
0.8120). However, CFA-injected rats exhibited a different profile,
with a slope being close to 0 (ascending: y ⫽ ⫺0.886 x ⫹ 5.672,
R 2 ⫽ 0.955; and descending: y ⫽ 0.831 x ⫹ 1.395, R 2 ⫽ 0.138).
When we combined the data from both dose–response sessions
and calculated intake for each dose, we observed that rats experiencing pain self-administered significantly more heroin at 200
g/kg/infusion (n ⫽ 10 –12/group, p ⫽ 0.002) compared with
4
Figure 5. Inflammatory pain increases heroin intake at high but not low doses under FR
schedules of reinforcement. A, Schematic of the experimental design is shown for the training
and dose–response tests of heroin self-administration. B, Paw withdrawal latencies (mean ⫾
SEM in seconds) to radiant thermal stimuli during training and dose–response sessions for
heroin self-administration. No differences from baseline latency were observed during training
with self administration; however, CFA-treated rats (red) showed a decrease in paw withdrawal
latency compared with saline-injected rats (black) 48 and 72 h after the injection. #p ⬍ 0.05,
differences between groups (two-way ANOVA followed by Bonferroni multiple comparisons).
*p ⬍ 0.05, differences within a group (two-way ANOVA followed by Bonferroni multiple comparisons). n ⫽ 5 or 6/group. C, Number of responses in the active (circle) versus inactive
(square) lever during the training period under fix-ratio FR1 and FR2 schedules of reinforcement. Data are mean ⫾ SEM; n ⫽ 11. D, Within-session dose–response curve in ascending (left
panel) and descending (right panel) order of presentation of the dose for control (black) and
CFA-treated (red) rats. Data are mean ⫾ SEM of the number of infusions in 1 h blocks for each
dose represented in semilogarithmic scale. Linear regressions are also represented in the
graphs. E, Total heroin intake (g) for each dose tested. Data are mean ⫾ SEM of the pooled
total heroin intake of both sessions performed per animal. Pain increased total intake when
exposed to 200 g/kg heroin. #p ⬍ 0.05, compared with control rats (two-way ANOVA with
repeated measures followed by one-way ANOVA with Bonferroni corrections for multiple comparisons). n ⫽ 5 or 6 per group. A significant effect of dose on total heroin intake was observed
for the pain group but not for the control group. *p ⬍ 0.05.

their control counterparts (Fig. 5E). CFA did not induce any
significant change in intake at 100 g/kg heroin, although a decrease was observed at 50 g/kg versus control rats. This effect
was not significant, however (Fig. 5E).
We conducted similar experiments using sucrose pellets as a
positive natural reinforcer (Fig. 6A). In these control experiments, the presence of pain did not alter responding for sucrose
when tested on the active lever according to an FR schedule of
reinforcement (n ⫽ 5 or 6, F(1,9) ⫽ 0.057, p ⫽ 0.822; Fig. 6B), the
inactive lever (n ⫽ 5 or 6, F(1,9) ⫽ 0.083, p ⫽ 0.799), or in the time
to complete the self-administration of 60 sucrose pellets (n ⫽ 4 or
5, F(1,7) ⫽ 0.004, p ⫽ 0.954; Fig. 6C). These data suggest that
inflammatory pain does not affect lever pressing for sucrose under an FR schedule of reinforcement.
Inflammatory pain reduces motivated behavior, and only a
high dose of heroin maintains motivation for heroin
We next investigated the effect of inflammatory pain on motivated behavior given the fact that DA levels, via MOR activation
the reward pathway, influence the motivation for drug intake
measured in a PR schedule of reinforcement (Roberts and Bennett, 1993). Because DA release was reduced, presumably via loss
of MOR function following the administration of 75 g/kg intravenous heroin, and it increased following the administration of
150 g/kg intravenous heroin in the presence of inflammatory
pain (Fig. 1 B, C), we hypothesized that motivation for 50 and 200
g/kg/infusion would be likewise affected. Rats were trained to
self-administer 50 g/kg/infusion heroin (n ⫽ 10) or sucrose
pellets (n ⫽ 10) under FR1, FR2, and FR5 schedules of responding for at least 11 sessions (Fig. 7 B, C). Afterward, rats underwent
a heroin (50 or 200 g/kg/infusion) or sucrose PR baseline session to measure initial ordinal value of the final ratio to which the
rat responded (PR step number). Following the baseline PR
training session, rats were injected with either saline or CFA in the
hindpaw. Forty-eight hours after the injection, rats were tested
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Figure 7. Inflammatory pain impacts motivated behavior. A, Schematic of the experimental design is shown for the training and PR sessions for heroin and sucrose self-administration. Number
of responses on the active lever (circle) versus the inactive lever (square) under FR1, FR2, and FR5 schedules of reinforcement with 50 g/kg/infusion heroin (B) or sucrose pellets (C) as the reinforcer
(data are mean ⫾ SEM). Effect of inflammatory pain on the PR step number (% from baseline) 48 h after saline (black represents baseline; gray represents after injection) or CFA injection (red
represents baseline; pink represents after injection) with heroin 50 g/kg/infusion (D), 200 g/kg/infusion (E), or sucrose pellets (F) as the reinforcer. *p ⬍ 0.05 versus baseline (two-way ANOVA
with repeated measures followed by Bonferroni corrections for multiple comparisons). n ⫽ 10 per group.

again under a PR schedule of reinforcement and the completed
PR step number was recorded and transformed to percentage of
baseline. Inflammatory pain reduced PR step number from baseline to 72% (PR step number: baseline: 14.2 ⫾ 0.9; after injection:
10.2 ⫾ 1.2) with sucrose as the reward (Fig. 7F; two-way ANOVA
for repeated measure: within-subjects effect of session, F(1,8) ⫽
8.421, p ⬍ 0.001; Bonferroni multiple comparisons, p ⫽ 0.020).
In rats trained with 50 g/kg/infusion (dependent rats), the presence of inflammatory pain reduced the PR step number from
baseline to 63% (PR step number: baseline 9.8 ⫾ 1.5; after injection: 6.5 ⫾ 1.4) with 50 g/kg/infusion heroin as the reinforcer
(Fig. 7D; two-way ANOVA for repeated measures; withinsubjects effect of session, F(1,8) ⫽ 20.954, p ⫽ 0.002 and interaction effect of session ⫻ group, F(1,8) ⫽ 15.493, p ⫽ 0.004,
Bonferroni correction for multiple comparisons, p ⫽ 0.011). Interestingly, this effect of inflammatory pain on motivated behavior for heroin was completely abolished when the heroin dose was
increased up to 200 g/kg/infusion (Fig. 7E). In this regard, no
significant differences were detected before and after CFA injection in the PR step reached by the rats with 200 g/kg/infusion

heroin as reward (PR step number: baseline 4.8 ⫾ 0.5; after injection 4.0 ⫾ 0.4; two-way ANOVA for repeated measures,
within-subject effect of session, F(1,8) ⫽ 0.260, p ⫽ 0.624; interaction effect of session ⫻ group, F(1,8) ⫽ 0.001, p ⫽ 0.978).

Discussion
Exposure to opioids in pain patients with a prior history of drug
use has been identified as a potential risk for opioid abuse and/or
relapse (Chang and Compton, 2013). The results presented here
provide new evidence that pain-induced MOR desensitization
affects opioid-evoked DA transmission within the reward pathway. This diminished DA release thereby affects the reinforcing
properties of heroin such that higher doses of the drug are necessary to produce reinforcing effects.
MOR function is reduced in the presence of
inflammatory pain
Opioid receptors, mainly MORs, located in the mesolimbic pathway, are thought to mediate the reinforcing properties of opioids,
natural reinforcers, and alcohol via regulation of DA extracellular
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levels within the NAc (Devine et al., 1993; Xiao and Ye, 2008; Le
Merrer et al., 2009; Giuliano et al., 2013). This effect is mediated
by the inhibition of GABA release in the VTA via the activation of
presynaptic MORs of GABA interneurons or GABA projections
from the rostromedial tegmental nucleus (RMTG), which then
leads to an increase in DA release in the NAc through a disinhibition mechanism (Johnson and North, 1992; Sánchez-Catalán
et al., 2014; Siuda et al., 2015) or local activation of MORs in the
NAc core and discrete areas of the NAc shell (Hipólito et al.,
2008).
Although clinical and preclinical reports have shown a decrease in DA signaling during pain conditions (Ozaki et al., 2003;
Jarcho et al., 2012; Wu et al., 2014), few studies have examined
whether this effect may be mediated by alterations in MOR function. Nonetheless, function of MORs has been evaluated mainly
in areas of the CNS involved in nociception. In an early study,
Zhang et al. (2004a) revealed that proinflammatory cytokines
desensitize MORs in DRG, providing a first insight into the effects of inflammatory pain on MOR function. Similar studies
have mainly investigated MOR function from a nociception
point of view in different nuclei of the CNS (Hurley and Hammond, 2001; Jongeling et al., 2009; Aoki et al., 2014). Cytokines
have also been investigated in the field of opioid addiction and
MOR function. Several studies show that the Toll-like receptor 4
may play an important role in opioid addiction and in opioidinduced analgesia via regulation of MOR function (for review, see
Hutchinson and Watkins, 2014).
By combining DA microdialysis with nociception sensitivity
measurements following intravenous heroin administration, we
were able to determine the effects of inflammatory pain on both
the reinforcing and the antinociceptive properties of heroin. Our
data clearly show that inflammatory pain induces robust alterations in opioid-evoked DA transmission within the mesolimbic
circuit, which affects the reinforcing properties of the opioid
without affecting its antinociceptive properties against thermal
hyperalgesia. Indeed, we found that rats in pain needed higher
doses of heroin to exhibit similar levels of extracellular DA in the
NAc to those observed in control rats. Because activation of
MORs in both NAc core and VTA increase DA extracellular levels
in NAc core (Spanagel et al., 1992; Hipólito et al., 2008), we used
the selective MOR agonist DAMGO microinjected directly into
the VTA to determine that inflammatory pain-induced changes
in heroin-evoked DA release are mediated via MORs in this region. Moreover, the administration of a 10 ⫻ higher dose of
DAMGO intra-VTA reversed the CFA-induced effects and also
confirmed that the desensitization of the MORs occurs mainly at
the VTA level. In a separate study, we examined the effects of the
intra-NAc core administration of DAMGO and demonstrated
that pain-induced loss of MOR-mediated modulation of DA
transmission was mainly localized in the VTA, and not the NAc.
Finally, to explore the underlying cellular mechanisms of
MOR function within the VTA, we conducted electrophysiological studies in saline and CFA-treated rats. Opioids directly inhibit ⬃50% of VTA neurons via an inwardly rectifying potassium
conductance (Margolis et al., 2014). However, because we used a
cesium-chloride-based internal solution in our recordings, we
can presume that any effects we observed were mediated by presynaptic actions of DAMGO. At a 1 M concentration, DAMGO
strongly inhibited presynaptic GABA release (reduced sIPSC frequency and amplitude) in neurons from saline, but not CFAtreated rats. The inability of DAMGO to reduce GABA release in
neurons from CFA-treated rats was partially restored by increasing the DAMGO concentration to 3 M (which significantly re-
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duced sIPSC frequency and amplitude). These findings
demonstrate that inflammatory pain is sufficient to induce presynaptic MOR desensitization in the lateral posterior VTA. The
loss of MOR regulation of GABA release could occur in both VTA
interneurons and other GABAergic projections to DA neurons.
Given the tight regulation of DA neuron firing by tonic GABA
release in the VTA, these results highlight an important regulatory role of MORs in the VTA during inflammatory pain. The
results of these physiological experiments are directly in line with
our microdialysis data.
Pain-induced dysregulation of MOR affects heroin intake
and motivation
It is well established that DA innervation in ventral striatum is
necessary for drug reward-related behaviors, such as drug selfadministration and conditioned place preference (Koob, 1992;
McBride et al., 1999). However, the role of DA transmission
within the NAc in opioid seeking has been a controversial topic
(for details, see Badiani et al., 2011). It has been reported that
fluctuations in DA levels in NAc correlate with heroin selfadministration behavior (Wise et al., 1995), MOR agonists are
readily self-administered into the NAc or the VTA (Phillips and
LePiane, 1980; Bozarth and Wise, 1981), and local infusion of
opioids into the NAc or the VTA produces conditioned place
preference (van der Kooy et al., 1982; Shippenberg et al., 1993;
Walker and Ettenberg, 2005). Furthermore, blockade of D1 receptors in the NAc core impairs discrete cue-induced reinstatement (Bossert et al., 2007), and targeted expression of MORs in
subsets of neurons within the ventral striatum restores opiate
reward (Cui et al., 2014). These previous studies show a role for
MOR within the DA mesolimbic pathway in the complex modulation of opiate seeking behavior. In our study, we demonstrated that inflammatory pain-induced dysregulation of MOR
function within the VTA can lead to alterations in opiate seeking
behavior.
Our self-administration studies indicate that the presence of inflammatory pain alters the patterns of heroin self-administration by
increasing the intake of high doses of the drug and maintaining
motivation only when a high dose of the drug is presented. Although previous studies have investigated the effect of neuropathic and inflammatory pain on the reinforcing and rewarding
effects of opioids in drug naive rodents using intravenous selfadministration, conditioned place preference, and microdialysis
(Ozaki et al., 2002; Martin et al., 2007; Wu et al., 2014), only two
of these studies examined more than one opioid dose. In the
study conducted by Martin et al. (2007), the maximum heroin
dose tested was 100 g/kg/infusion, which was the only dose
capable of maintaining heroin self-administration following spinal nerve ligation. Consequently, these authors reported that
higher doses of opioids (i.e., up to 100 g/kg/infusion) are required to maintain opioid self-administration in neuropathic
pain. However, our findings here show that the presentation of
even higher doses of heroin (i.e., up to 200 g/kg/infusion) dramatically increase opioid intake in the presence of inflammatory
pain, an effect previously overlooked due to the limited dose
range tested. In one sense, our data could seem counterintuitive
because one would expect that heroin would have become more
reinforcing because of pain alleviation (Wood, 2008). However,
our microdialysis and electrophysiology data provide a mechanistic explanation, namely, a decrease in MOR function in the
VTA that could explain the observed alterations in heroin intake.
One plausible explanation of the pain-mediated desensitization
that we observed is that the change in the endogenous opioid
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levels induced by pain (Zubieta et al., 2001) may finally result in
different pharmacology of the opioid receptors. The increased
levels of endogenous opioids may continuously activate MOR in
the mesolimbic pathway that may induce depletion of DA and
desensitization of MOR due to continuous activation of the receptor (Gainetdinov et al., 2004).
The PR self-administration results further support the notion
that inflammatory pain desensitizes MORs in the reward pathway by reducing the motivation to work for both drug and natural reinforcers. Furthermore, the observed differential effects of
pain on FR versus PR schedules of reinforcement reveal a disruption in the animal’s ability to determine the effort required to
obtain rewards or to become motivated in performing the necessary actions to obtain rewards. Together, these behavioral results
suggest that pain may act to trigger anhedonic-like behavior
(Der-Avakian and Markou, 2012) or loss of effort-related motivation and decision-making (Randall et al., 2014; Pardo et al.,
2015). Furthermore, these data are consistent with studies in humans that show a potential link between chronic pain and affective disorders (Jarcho et al., 2012). More interesting is that a
fourfold increase in heroin dose reversed this pain-induced reduced
motivation, providing supporting evidence that a change in the sensitivity to opioids could ultimately lead opioid-abusing individuals
in pain to seek and consume very high doses of opioids.
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